Neurocrine Biosciences, Inc.
NBIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,355,300 | $1,887,100 | $1,488,700 | $1,133,500 |
| % Growth | 24.8% | 26.8% | 31.3% | – |
| Cost of Goods Sold | $34,000 | $39,700 | $23,200 | $14,300 |
| Gross Profit | $2,321,300 | $1,847,400 | $1,465,500 | $1,119,200 |
| % Margin | 98.6% | 97.9% | 98.4% | 98.7% |
| R&D Expenses | $731,100 | $565,000 | $463,800 | $328,100 |
| G&A Expenses | $816,200 | $0 | $0 | $0 |
| SG&A Expenses | $1,007,200 | $887,600 | $752,700 | $583,300 |
| Sales & Mktg Exp. | $191,000 | $0 | $0 | $0 |
| Other Operating Expenses | $12,500 | $143,900 | $0 | $105,300 |
| Operating Expenses | $1,750,800 | $1,596,500 | $1,216,500 | $1,016,700 |
| Operating Income | $570,500 | $250,900 | $249,000 | $102,500 |
| % Margin | 24.2% | 13.3% | 16.7% | 9% |
| Other Income/Exp. Net | -$84,500 | $81,200 | -$35,100 | -$1,100 |
| Pre-Tax Income | $486,000 | $332,100 | $213,900 | $101,400 |
| Tax Expense | $144,700 | $82,400 | $59,400 | $11,800 |
| Net Income | $341,300 | $249,700 | $154,500 | $89,600 |
| % Margin | 14.5% | 13.2% | 10.4% | 7.9% |
| EPS | 3.4 | 2.56 | 1.61 | 0.95 |
| % Growth | 32.8% | 59% | 69.5% | – |
| EPS Diluted | 3.29 | 2.47 | 1.56 | 0.92 |
| Weighted Avg Shares Out | 100,400 | 97,700 | 95,800 | 94,600 |
| Weighted Avg Shares Out Dil | 103,700 | 101,000 | 98,900 | 97,900 |
| Supplemental Information | – | – | – | – |
| Interest Income | $91,000 | $0 | $11,200 | $0 |
| Interest Expense | $126,600 | $4,600 | $7,100 | $25,800 |
| Depreciation & Amortization | $27,100 | $21,300 | $15,600 | $10,900 |
| EBITDA | $639,700 | $416,100 | $264,600 | $138,100 |
| % Margin | 27.2% | 22% | 17.8% | 12.2% |